Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales
China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half...
Chongqing Genrix Bio Pharmaceutical’s GR1802 Injection Receives NMPA Approval for Seasonal Allergic Rhinitis in Adolescents
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that its investigational product, GR1802...
Santhera Pharmaceuticals Signs Exclusive Agreement with Uniphar for AGAMREE Distribution in Middle East
Swiss firm Santhera Pharmaceuticals (SWX: SANN), a leader in innovative therapies for rare diseases, has...
Vivatides Therapeutics Completes Multi-Million Dollar Seed Financing to Advance Nucleic Acid Delivery Platform
Biopharmaceutical company Vivatides Therapeutics has successfully completed a multi-million dollar seed round financing led by...
China Unveils Ten Measures to Boost Family Doctor Contract Services
In a significant move to enhance the quality and accessibility of primary healthcare, the National...
Hunan FangSheng Pharmaceutical to Acquire JAK Inhibitor Patent Rights for RMB 80 Million
Hunan FangSheng Pharmaceutical Co., Ltd. (SHA: 603998) announced today that it has reached an agreement...
Haihe Biopharma Seeks Japan Approval for Risovalisib in PIK3CA-Mutated Ovarian Cancer
Haihe Biopharma Co., Ltd. has filed a market application with Japan’s Ministry of Health, Labour...
XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea’s leading pharmaceutical company, Dong-A...
Sino Biopharm’s LM-302 Shows Promising Results in Phase III Trials for Gastric Cancer
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that LM-302, an innovative antibody-drug conjugate (ADC) developed...
GoodRx and Novo Nordisk Introduce $499 Monthly Pricing for Semaglutide Pens
Goodrx Holdings Inc (NASDAQ: GDRX), the leading platform for medication savings in the U.S., has...
InnoCare Pharma’s Orelabrutinib Powers 74.3% Revenue Surge in 2025 H1
Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has unveiled its 2025 interim results, showcasing a...
China’s Zelgen Secures FDA IND Approval for Triple-Targeted Cancer Drug ZGGS34
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) and its subsidiary Gensun Biopharma Inc. announced...
Hansoh’s Ameile Fuels Revenue Growth to RMB 7.434 Billion in H1 2025
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) reported unaudited interim results for the six...
Sichuan Kelun-Biotech Reports H1 Revenue Drop, Advances Key Drug Commercialization
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) released its financial results for the first half...
WuXi Biologics Reports 16.1% Revenue Growth in H1 2025, Launches WuXiHigh 2.0 Platform
WuXi Biologics (Cayman) Inc. (HKG: 2269), a leading global Contract Research, Development and Manufacturing Organization...
RemeGen’s RC148 Granted Breakthrough Therapy Designation for NSCLC Treatment
RemeGen Co., Ltd. (SHA: 688331, HKG: 9995), a China-based biotech company, announced that its novel...
Shandong Lukang’s CIGB-814 Starts Phase 1 Trial for Rheumatoid Arthritis Treatment
Shandong Lukang Pharmaceutical Co., Ltd. (SHA: 600789) announced that its CIGB-814 immunomodulator has commenced a...
HutchMed Completes Patient Enrollment for Orpathys and Tagrisso Combination Study
Chinese pharmaceutical company HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced the completion of patient...
Sino Biopharmaceutical Reports 10.7% Revenue Growth and 140.2% Profit Surge in H1 2025
China-based Sino Biopharmaceutical Limited (HKG: 1177) announced its financial results for the first half of 2025....
Kangtai Biological Gains NMPA Approval for Trivalent Influenza Vaccine Clinical Trial
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) announced that it has received approval from...